Compares JNJ-79635322 with teclistamab in adults with relapsed or hard-to-treat multiple myeloma
Compares JNJ-79635322 with another antibody therapy in adults with relapsed multiple myeloma.
Plain-language title generated from the registry record
Registry title: A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
Key facts
- Where
- Ann Arbor, Atlanta, Austin, Baltimore, Boston, Brooklyn, Chapel Hill, Cleveland, Dallas, Denver, Duarte, Durham, Farmington, Fort Myers, Houston, Iowa City, Irvine, Jacksonville, Kansas City, Little Rock, Los Angeles, Louisville, Miami, Milwaukee, Mineola, Nashville, New Haven, New York, Philadelphia, Phoenix, Portland, Rochester, Salt Lake City, San Antonio, San Francisco, Tampa, Waukee, and Zion, United StatesSee the 47 sites
- Phase
- Phase 3
Where in United States
- University of Michigan Rogel Cancer CenterAnn Arbor, United StatesTaking people
- Emory UniversityAtlanta, United StatesTaking people
- St. David's South Austin Medical CenterAustin, United StatesTaking people
- University of Maryland School of MedicineBaltimore, United StatesTaking people
- Beth Israel Deaconess Medical CenterBoston, United StatesTaking people
- Boston University Medical CenterBoston, United StatesTaking people
- Dana-Farber Cancer InstituteBoston, United StatesTaking people
- Mount Sinai BrooklynBrooklyn, United StatesTaking people
- University of North CarolinaChapel Hill, United StatesTaking people
- Cleveland ClinicCleveland, United StatesTaking people
- Baylor University Medical CenterDallas, United StatesTaking people
- UT Southwestern Medical CenterDallas, United StatesTaking people
- Colorado Blood Cancer InstituteDenver, United StatesTaking people
- City of Hope - DuarteDuarte, United StatesTaking people
- Durham VAMCDurham, United StatesTaking people
- University of Connecticut Health CenterFarmington, United StatesTaking people
- Florida Cancer Specialists & Research InstituteFort Myers, United StatesTaking people
- MD Anderson Cancer CenterHouston, United StatesTaking people
- University of Iowa Hospital and ClinicsIowa City, United StatesTaking people
- City of Hope Orange County Lennar Foundation Cancer CenterIrvine, United StatesTaking people
- Mayo Clinic- JacksonvilleJacksonville, United StatesTaking people
- University of Kansas Cancer CenterKansas City, United StatesTaking people
- UAMSLittle Rock, United StatesTaking people
- UCLA Medical CenterLos Angeles, United StatesTaking people
- USC / Norris Comprehensive Cancer CenterLos Angeles, United StatesTaking people
- Norton Cancer InstituteLouisville, United StatesTaking people
- University of Miami HospitalMiami, United StatesTaking people
- Medical College of WisconsinMilwaukee, United StatesTaking people
- NYU WinthropMineola, United StatesTaking people
- SCRI Oncology PartnersNashville, United StatesTaking people
- Vanderbilt University Medical CenterNashville, United StatesTaking people
- Yale Cancer CenterNew Haven, United StatesTaking people
- Icahn School of Medicine at Mount SinaiNew York, United StatesTaking people
- Laura and Isaac Perlmutter Cancer Center NYU ACCNew York, United StatesTaking people
- Memorial Sloan-Kettering Cancer CenterNew York, United StatesTaking people
- Mount Sinai ChelseaNew York, United StatesTaking people
- Fox Chase Cancer CenterPhiladelphia, United StatesTaking people
- Thomas Jefferson University HospitalPhiladelphia, United StatesTaking people
- Mayo Clinic PhoenixPhoenix, United StatesTaking people
- Oregon Health and Science UniversityPortland, United StatesTaking people
- Mayo Clinic - RochesterRochester, United StatesTaking people
- Huntsman Cancer InstituteSalt Lake City, United StatesTaking people
- Texas Transplant InstituteSan Antonio, United StatesTaking people
- University of California San FranciscoSan Francisco, United StatesTaking people
- Moffit Cancer CenterTampa, United StatesTaking people
- Mission Cancer BloodWaukee, United StatesTaking people
- City of Hope - ChicagoZion, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Janssen Research & Development, LLC
- Trial code
- NCT07258511EU 2025-522007-18-00
- Record updated
- 3 November 2026
- Original description
The purpose of this study is to evaluate how well JNJ-79635322 works when compared with an anti-B-cell maturation antigen (BCMA)xCD3 bispecific antibody.Read full original descriptionShow less
A Phase 3 Randomized Study Comparing JNJ-79635322 and an Anti-BCMAxCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma Who Have Received at Least 3 Prior Lines of Therapy Including a PI, an IMiD, and an Anti CD38 Antibody
The purpose of this study is to evaluate how well JNJ-79635322 works when compared with an anti-B-cell maturation antigen (BCMA)xCD3 bispecific antibody.
Inclusion:; Documented diagnosis of multiple myeloma (MM) as defined by the criteria below:; MM diagnosis according to the international myeloma working group (IMWG) diagnostic criteria; Measurable disease at screening as assessed by central laboratory; Received at least 3 prior lines of antimyeloma therapy including a proteasome inhibitor (PI), an immunomodulatory drug (IMiD), and an anti-cluster of differentiation (CD)38 antibody; Documented evidence of progressive disease (PD) or failure to achieve a response to the last line of therapy based on investigator's determination of response by IMWG criteria; Toxicity related to previous anticancer therapy must have resolved to Grade 1 or better; Have an eastern cooperative oncology group (ECOG) performance status of 0 to 2 at screening and immediately before the start of study treatment administration; Exclusion:; Active hepatitis of infectious origin; Known active or prior central nervous system (CNS) involvement or exhibits clinical signs of meningeal involvement of MM; Suspected or known allergies, hypersensitivity, or intolerance to the excipients of JNJ-79635322 and Teclistamab; Major surgery, (example, requiring general anesthesia) within 2 weeks before first dose, or will not have fully recovered from surgery, or has surgery planned during the time the participant is expected to participate in the study; Received or plans to receive any live, attenuated vaccine within 4 weeks before the first dose of study treatment, or during study treatment.